|
|||||||||||||||
|
|
Oct
23 |
Friday October 23, 2009 ****************************************************************** The Medicines Company announced that the Committee for Medicinal Products for Human Use has granted a positive opinion applicable to all Member States of the European Union/European Economic Area that will extend the use of Angiox to include patients with heart attacks undergoing emergency heart procedures called primary percutaneous coronary intervention. The basis of this approval is the landmark HORIZONS-AMI study which was the first drug trial to demonstrate a reduction in deaths from heart attacks in patients undergoing emergency PCI. The trial showed that patients treated with Angiox compared with today?s leading treatment - heparin plus a platelet glycoprotein IIb/IIIa inhibitor ? were more likely to survive and had less frequent severe bleeds.
"Climate change is the defining issue for our generation of American leadership, and further delay in addressing this challenge will be self-defeating in that it would require a severity of policy that would be damaging to the American public in a way that addressing the challenge now would not be," said David Crane, President and CEO, NRG Energy, Inc. "Sound federal climate change legislation has many important components but a bedrock principle of such legislation must be that it will promote private sector investment in vital low and no carbon technologies that will create new jobs and provide a foundation for economic recovery. Legislation must also protect consumers, vulnerable communities and businesses while ensuring economic sustainability and environmental effectiveness."
October new-vehicle retail sales are expected to come in at 651,600 units, which represent a seasonally adjusted annualized rate (SAAR) of 8.3 million units. With fleet volume down only 4 percent from one year ago, total sales for October are projected to come in at 816,600 units, down 6 percent from October 2008.
Better than Expected 2009 Sales Pipeline China Crescent is a systems integration service provider in China that markets technology outsourcing services that include the sale and service of brand name technologies such as Microsoft, Oracle, Cisco, IBM, HP and Dell. The Company has been marketing a new outsourcing service since the beginning of this year and has already signed $30 million in total revenue value over three years with Beijing Chuangzhitongda Technology Development through the outsourcing services offering. The Company also recently announced a letter of intent to provide outsourcing services to Aoyuan Electronic Co. ltd in Dalian, China, for $36 million over three years.
***********Advertisement***********
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.Stock Hot Tips publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold StockHotTips.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has received five thousand dollars from Consorteum Holdings Inc. for 30 days of advertisement. Crown Equity Holdings, Inc. (CRWE.OB) has received 78,000 free trading and 500,000 144 (restricted) shares from a third party advertisement services for 6 months of advertising services Consorteum Holdings Inc,(CSRH.OB)
|
|